Based on real-world data, Johnson & Johnson (NYSE:JNJ) announced Wednesday its prostate cancer therapy Erleada (apalutamide) ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis ...

Kirkland & Ellis has successfully defended the validity of a pharmaceutical company's patent in London's High Court, ...

On September 13, 2024, ESSA Pharma, Inc. (NASDAQ:EPIX) announced that updated Phase 1/2 clinical trial data for masofaniten (formerly EPI-7386) in combination with enzalutamide (Enz) was presented ...

Wednesday, Johnson & Johnson (NYSE:JNJ) revealed results from a head-to-head study of Erleada (apalutamide) compared to ...

Investigators examined overall survival among real-world patients with metastatic prostate cancer (mCSPC) initiating enzalutamide vs apalutamide.

Pfizer announces positive results from phase 3 TALAPRO-2 trial of Talzenna in combination with Xtandi in patients with mCRPC: New York Friday, October 11, 2024, 09:00 Hrs [IST] Pf ...

Zydus Lifesciences share price trading maginally lower in the opening trade on October 3 despite the company received ...

(RTTNews) - Johnson & Johnson (JNJ), Wednesday announced results from a head-to-head study, demonstrating statistically significant overall survival benefit in patients on Erleada at 24 months ...

BARCELONA, Spain — Adding bone-targeting radium-223 (Ra223) to the androgen receptor pathway inhibitor enzalutamide (Xtandi) in patients with metastatic castration-resistant prostate cancer and ...

Abiraterone acetate plus prednisone and enzalutamide improve overall survival (OS) and radiological progression-free survival (rPFS) in docetaxel-pretreated patients. Abiraterone acetate plus ...